VivoSeq
Neurology

Progressive Supranuclear Palsy

34

Pipeline Programs↗

8

Active Trials↗

19

Companies Involved↗

Progressive Supranuclear Palsy is a moderately active landscape with 34 programs across 19 companies. The most active players are UCB, Avid Radiopharmaceuticals, Roche. 4 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

55/100

Pipeline Velocity

22/100

Mech. Concentration

11/100

Completion Rate

81/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

UCB logo

UCB

2 programs

Phase 1A

Avid Radiopharmaceuticals

1 program

Phase 1Roche logo

Roche

1 program

Phase 1CSL Behring logo

CSL Behring

1 program

Phase 1AbbVie logo

AbbVie

2 programs

Phase 2Biogen logo

Biogen

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

90%

Small molecule

28 of 31 classified programs — the dominant modality here.

10%ALL OTHERSPeptide26%Monoclonal antibody13%

Small molecule leads; the ring shows all 31 classified programs, each share of the total. Modality classified for 89% of 37 pipeline programs.

Analysis

Trial Status

38

clinical trials

Completed21 · 55%
Terminated5 · 13%
Unknown status4 · 11%
Not yet recruiting3 · 8%
Active, not recruiting3 · 8%
Recruiting2 · 5%

Clinical Trials

Trial Activity

38 trials

A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
Recruiting·MMayo Clinic·N/A·NCT02605785·332 enrolled
A Phase III, Randomized, Placebo-controlled, Parallel Group, Double-blind Study to Evaluate the Efficacy and Safety of NIO752 in Participants With Progressive Supranuclear Palsy Followed by an Open Label Extension
Recruiting·Novartis logoNovartis·Phase 3·NCT07498426·300 enrolled
A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
Active, not recruiting·—·Phase 2·NCT06355531·241 enrolled
A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy
Active, not recruiting·UCB logoUCB·Phase 1·NCT04658199·19 enrolled
AMX0035 and Progressive Supranuclear Palsy
Active, not recruiting·AAmylyx Pharmaceuticals Inc.·Phase 2/3·NCT06122662·110 enrolled
The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1
Not yet recruiting·—·Phase 2·NCT07217665·146 enrolled
The Progressive Supranuclear Palsy Clinical Trial Platform
Not yet recruiting·—·Phase 2·NCT07173803·440 enrolled
The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31
Not yet recruiting·—·Phase 2·NCT07264283·147 enrolled
GV1001 Subcutaneous(SC) for the Treatment of Progressive Supranuclear Palsy (PSP)
Completed·GGemVax & Kael·Phase 2·NCT05819658·78 enrolled
Safety, Tolerability, and Efficacy of Two Different Oral Doses of NP031112 Versus Placebo in the Treatment of Patients With Mild-to-Moderate Progressive Supranuclear Palsy
Completed·NNoscira SA·N/A·NCT01049399·146 enrolled
Continuously Infused Recombinant-Methionyl Human Glial Cell Line-Derived Neurotrophic Factor (GDNF) to Treat Progressive Supranuclear Palsy
Completed·National Institute of Neurological Disorders and Stroke (NINDS)·Phase 2·NCT00005903·15 enrolled
A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)
Completed·UCB logoUCB·Phase 1·NCT04185415·25 enrolled
Extension Study of ABBV-8E12 in Patients With Progressive Supranuclear Palsy (PSP) Who Completed Study C2N-8E12-WW-104
Completed·AbbVie logoAbbVie·Phase 1·NCT03413319·3 enrolled
Trial of Valproic Acid in Patients With Progressive Supranuclear Palsy (Depakine)
Completed·NNantes University Hospital·Phase 2·NCT00385710·28 enrolled
A 6 Month, Open-Label, Pilot Futility Clinical Trial of Oral Salsalate for Progressive Supranuclear Palsy
Completed·—·Phase 1·NCT02422485·10 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)